Top Markets
Coin of the day
Lannett Company, Inc. Lannett Company, Inc.

Lannett Company, Inc.

LCI
Rang in aandelen #35166
Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to... Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.
Aandeelprijs
$0.028
Laatst gesynchroniseerd: 2023-05-23
Marktkapitalisatie
$4.34M
Verandering (1 dag)
40.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Lannett Company, Inc. (LCI)

Categorie

P/S-ratio voor Lannett Company, Inc. (LCI)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Lannett Company, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Lannett Company, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten